APA (7th ed.) Citation

L, L., W, C., D, I., CR, K., H, K., TM, M., . . . A, G. (2025). Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate cancer and prostatic diseases, 28(2), 427. https://doi.org/10.1038/s41391-024-00888-y

Chicago Style (17th ed.) Citation

L, Lenz, et al. "Active Surveillance Selection and 3-year Durability in Intermediate-risk Prostate Cancer Following Genomic Testing." Prostate Cancer and Prostatic Diseases 28, no. 2 (2025): 427. https://doi.org/10.1038/s41391-024-00888-y.

MLA (9th ed.) Citation

L, Lenz, et al. "Active Surveillance Selection and 3-year Durability in Intermediate-risk Prostate Cancer Following Genomic Testing." Prostate Cancer and Prostatic Diseases, vol. 28, no. 2, 2025, p. 427, https://doi.org/10.1038/s41391-024-00888-y.